Bacterial Pathogens and Death during the 1918 Influenza Pandemic
To the Editor: A review of recut lung-tissue specimens and published autopsy series from the 1918 influenza pandemic suggests that secondary bacterial pneumonia 1 was an important cause of death, consistent with our preliminary analysis of antemortem blood cultures and the time to death of the patients. 2 We review here studies that reported more than 10 sterile-site antemortem cultures from adults with pneumonia and those without pneumonia in an extensive archive of articles about the 1918 pandemic in any language (www3.niaid.nih.gov/topics/Flu/1918/bibliography .htm). Bacteria were recovered in only a few blood cultures for patients who had influenza but not pneumonia (mean among all the reports, <1%) but were more commonly isolated from cultures of samples from patients with influenza-associated pneumonia (mean, 16%; range, 2 to 50), particularly those who died (40%) ( Table 1 and the Supplementary Appendix, available with the full text of this article at NEJM.org). Moreover, 80% of pleural-fluid and lung cultures from patients with pneumonia yielded bacteria (range, 57 to 100). The studies with lower reported rates of positive culture may have obtained cultures early, overdiagnosed pneumonia, or had problems culturing fastidious organisms. Streptococcus pneumo niae and hemolytic streptococci (probably S. pyo genes) comprised 71% and 28% of positive cultures (whether blood or pleural and lung), respectively; Staphylococcus aureus was less common among the cultures (1%).
The insensitivity of blood culture for identifying pneumococcal pneumonia (with detection in only approximately 3% and 20% of cultures from children and adults, respectively) as compared with the high percentage of positive lung cultures 3 suggests that bacterial infections, especially pneumococcal infections, were a major cause of influenzaassociated pneumonia and death among both military personnel and civilians in 1918-1919. The distribution of pneumococcal serotypes shifted toward less invasive serotypes during that period as compared with the pre-1918 period, suggesting that the 1918 influenza virus increased host susceptibility to less-invasive pneumococci. 2 Children receiving pneumococcal conjugate vaccine in a double-blind, randomized trial had a 45% reduction in the rate of hospitalization for seasonal influenza-related pneumonia. 4 Recent use of pneumococcal conjugate vaccine in developed countries, as well as the availability of antibiotics since the 1940s, influenza vaccination, use of antiviral agents, and reduced virulence of pandemic viruses, may all have reduced the mortality associated with influenza pandemics. Although viral pneumonitis alone has caused deaths, a recent report from the Centers for Disease Control and Prevention 5 showed that 29% of the patients who died from infection with the 2009 pandemic influenza A (H1N1) virus had evidence of bacterial infection with pneumococci predominantly of types not present in the conjugate vaccine. The currently increased incidence of staphcorrespondence ylococcal infections may reflect the resistance of staphylococci to community antibiotic use and a higher probability of culture being performed, either after death or after the initiation of antibiotic therapy.
The burden of death from pneumonia-related infection with the 2009 pandemic influenza A (H1N1) virus could be greater in developing countries with high rates of carriage of pneumococcal bacteria among both adults and children and limited availability of pneumococcal conjugate vaccine and antibiotics. The historical data suggest that administration of pneumococcal vaccine and antibiotic therapy may be important to reduce mortality from influenza-associated pneumonia. 
